Candriam S.C.A. Boosts Stock Holdings in Becton, Dickinson and Company $BDX

Candriam S.C.A. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 133.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 34,745 shares of the medical instruments supplier’s stock after acquiring an additional 19,836 shares during the period. Candriam S.C.A.’s holdings in Becton, Dickinson and Company were worth $5,463,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Sequoia Financial Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 24.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 13,444 shares of the medical instruments supplier’s stock worth $2,114,000 after acquiring an additional 2,684 shares in the last quarter. Equitable Trust Co. lifted its holdings in shares of Becton, Dickinson and Company by 11.3% in the 1st quarter. Equitable Trust Co. now owns 13,037 shares of the medical instruments supplier’s stock valued at $2,050,000 after purchasing an additional 1,320 shares during the last quarter. Hsbc Holdings PLC boosted its position in shares of Becton, Dickinson and Company by 15.5% in the 1st quarter. Hsbc Holdings PLC now owns 682,358 shares of the medical instruments supplier’s stock valued at $107,149,000 after purchasing an additional 91,450 shares during the period. Bernzott Capital Advisors grew its stake in Becton, Dickinson and Company by 61.5% during the 1st quarter. Bernzott Capital Advisors now owns 46,137 shares of the medical instruments supplier’s stock worth $7,254,000 after buying an additional 17,564 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV lifted its stake in Becton, Dickinson and Company by 67.8% in the first quarter. Azzad Asset Management Inc. ADV now owns 42,248 shares of the medical instruments supplier’s stock valued at $6,643,000 after buying an additional 17,069 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 1.3%

BDX opened at $153.88 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The firm’s 50 day moving average is $148.34 and its 200-day moving average is $167.31. The firm has a market capitalization of $42.40 billion, a P/E ratio of 38.96, a P/E/G ratio of 10.75 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent research reports. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Piper Sandler cut their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Bank of America reduced their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Finally, Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $180.29.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,188 shares of company stock valued at $765,120 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.